<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>200072</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>9239396</PubmedId>
            <Abstract>The present study was designed to determine if highly conserved hepatitis B virus (HBV)-derived peptides that bind multiple HLA class I alleles with high affinity are recognized as cytotoxic T lymphocyte (CTL) epitopes in acutely infected patients. Peripheral blood mononuclear cells from 67 patients with acute hepatitis B, and 12 patients convalescent from acute hepatitis B, were stimulated with three panels of peptides, each of which bind with high affinity to several class I alleles from the HLA-A2-, HLA-A3-, or HLA-B7-supertypes. In these patients, 8 of the 19 peptides tested were found to represent CTL epitopes recognized by two or more alleles in each supertype. Two sets of nested peptides were recognized in the context of alleles with completely unrelated peptide binding specificities. Finally, promiscuous recognition by the same CTL of a given peptide presented by target cells expressing different A2 subtypes was also commonly observed. In conclusion, several HBV-specific CTL epitopes, recognized by acutely infected or convalescent patients in the context of a wide range of HLA alleles have been identified. These results demonstrate the functional relevance of the supertype grouping of HLA class I molecules in a human viral disease setting. Furthermore, they represent a significant advance in the development of a totally synthetic vaccine to terminate chronic HBV infection and support the feasibility of a systematic approach to development of similar vaccines for prevention and treatment of other chronic viral infections.</Abstract>
            <ArticleYear>1997</ArticleYear>
            <ArticlePages>503-13</ArticlePages>
            <ArticleTitle>Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Bertoni</LastName>
                    <ForeName>R</ForeName>
                </Author>
                <Author>
                    <LastName>Sidney</LastName>
                    <ForeName>J</ForeName>
                </Author>
                <Author>
                    <LastName>Fowler</LastName>
                    <ForeName>P</ForeName>
                </Author>
                <Author>
                    <LastName>Chesnut</LastName>
                    <ForeName>R W</ForeName>
                </Author>
                <Author>
                    <LastName>Chisari</LastName>
                    <ForeName>F V</ForeName>
                </Author>
                <Author>
                    <LastName>Sette</LastName>
                    <ForeName>A</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA.</Affiliations>
            <ArticleChemicalList>HLA Antigens;Histocompatibility Antigens Class I;Peptides;Viral Proteins</ArticleChemicalList>
            <ArticleMeshHeadingsList>Acute Disease; Alleles; Cytotoxicity, Immunologic; HLA Antigens(immunology); Hepatitis B(immunology; physiopathology); Hepatitis B virus; Histocompatibility Antigens Class I(genetics; immunology); Humans; Peptides(genetics; immunology); Prognosis; T-Lymphocytes(immunology); Viral Proteins(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>100</Volume>
                <Issue>3</Issue>
                <Title>The Journal of clinical investigation</Title>
                <Issn>0021-9738</Issn>
                <MedlineTa>J Clin Invest</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ALMPLYACI</LinearSequence>
                        <StartingPosition>642</StartingPosition>
                        <EndingPosition>650</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAA10434.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>2758</EpitopeId>
                <ReferenceStartingPosition>642</ReferenceStartingPosition>
                <ReferenceEndingPosition>650</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356845</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>203</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 642</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ALMPLYACI</LinearSequence>
                                        <StartingPosition>642</StartingPosition>
                                        <EndingPosition>650</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>1</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.  The majority of responsiveness was observed in individuals with the A*0201 background.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1353499</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>143</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 642</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ALMPLYACI</LinearSequence>
                                        <StartingPosition>642</StartingPosition>
                                        <EndingPosition>650</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>13</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>15.4</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.  The majority of responsiveness was observed in individuals with the A*0201 background.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356844</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>200</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 642</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ALMPLYACI</LinearSequence>
                                        <StartingPosition>642</StartingPosition>
                                        <EndingPosition>650</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>1</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.  The majority of responsiveness was observed in individuals with the A*0201 background.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203848</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>10.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>143</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203850</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>3.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>201</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203852</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>851.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>231</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203849</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>126.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>200</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203851</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>148.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>204</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>DPSRGRLGL</LinearSequence>
                        <StartingPosition>778</StartingPosition>
                        <EndingPosition>786</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAA10434.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>9770</EpitopeId>
                <ReferenceStartingPosition>778</ReferenceStartingPosition>
                <ReferenceEndingPosition>786</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203854</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>195</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203855</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>40</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203857</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>45</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203856</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>44</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203853</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>458.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>251</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FLLSLGIHL</LinearSequence>
                        <StartingPosition>562</StartingPosition>
                        <EndingPosition>570</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAP79852.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>16751</EpitopeId>
                <ReferenceStartingPosition>562</ReferenceStartingPosition>
                <ReferenceEndingPosition>570</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356847</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>203</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FLLSLGIHL</LinearSequence>
                                        <StartingPosition>562</StartingPosition>
                                        <EndingPosition>570</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAP79852.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>1</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.  The majority of responsiveness was observed in individuals with the A*0201 background.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356846</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>200</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FLLSLGIHL</LinearSequence>
                                        <StartingPosition>562</StartingPosition>
                                        <EndingPosition>570</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAP79852.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>1</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.  The majority of responsiveness was observed in individuals with the A*0201 background.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1353498</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>143</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FLLSLGIHL</LinearSequence>
                                        <StartingPosition>562</StartingPosition>
                                        <EndingPosition>570</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAP79852.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>13</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>9</NumberOfSubjectsResponded>
                            <ResponseFrequency>69.2</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.  The majority of responsiveness was observed in individuals with the A*0201 background.  This epitope was found to be degenerate, recognized in the context of multiple supertype alleles.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203859</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>4300.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>200</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203862</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>11429.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>231</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203858</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>7.7</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>143</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203861</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>34.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>204</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203860</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>1000.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>201</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FLLTRILTI</LinearSequence>
                        <StartingPosition>183</StartingPosition>
                        <EndingPosition>191</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>BAF48755.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>16755</EpitopeId>
                <ReferenceStartingPosition>183</ReferenceStartingPosition>
                <ReferenceEndingPosition>191</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1353495</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>143</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FLLTRILTI</LinearSequence>
                                        <StartingPosition>183</StartingPosition>
                                        <EndingPosition>191</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>BAF48755.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>18</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>12</NumberOfSubjectsResponded>
                            <ResponseFrequency>66.7</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.  The majority of responsiveness was observed in individuals with type A*0201, but was also observed in 2 A*0205/6 individuals.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356848</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>200</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FLLTRILTI</LinearSequence>
                                        <StartingPosition>183</StartingPosition>
                                        <EndingPosition>191</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>BAF48755.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>1</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.  The majority of responsiveness was observed in individuals with the A*0201 background.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356849</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>203</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FLLTRILTI</LinearSequence>
                                        <StartingPosition>183</StartingPosition>
                                        <EndingPosition>191</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>BAF48755.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>4</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>50</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.  The majority of responsiveness was observed in individuals with the A*0201 background.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203865</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>1.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>201</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203867</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>231</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203863</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>9.8</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>143</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203866</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>38.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>204</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203864</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>100.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>200</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FLPSDFFPSV</LinearSequence>
                        <StartingPosition>18</StartingPosition>
                        <EndingPosition>27</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAB41699.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>16833</EpitopeId>
                <ReferenceStartingPosition>18</ReferenceStartingPosition>
                <ReferenceEndingPosition>27</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356850</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>200</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Core 18</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FLPSDFFPSV</LinearSequence>
                                        <StartingPosition>18</StartingPosition>
                                        <EndingPosition>27</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAB41699.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>1</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.  The majority of responsiveness was observed in individuals with the A*0201 background.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Tables IV, V and VI</LocationOfData>
                        <TCellId>1353494</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>143</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Core 18</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FLPSDFFPSV</LinearSequence>
                                        <StartingPosition>18</StartingPosition>
                                        <EndingPosition>27</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAB41699.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>25</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>22</NumberOfSubjectsResponded>
                            <ResponseFrequency>88</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.  The majority of responsiveness was observed in individuals with the A*0201 background, but was also observed in three A*0205/6 individuals.  This epitope was found to be degenerate, recognized in the context of multiple supertype alleles.  Degenerate immunogenicity could be expanded for epitopes by nesting HLA motifs: FLPSDFFPSV with LPSDFFPSV.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356851</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>203</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Core 18</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FLPSDFFPSV</LinearSequence>
                                        <StartingPosition>18</StartingPosition>
                                        <EndingPosition>27</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAB41699.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>6</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>50</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.  The majority of responsiveness was observed in individuals with the A*0201 background.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203869</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>2.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>200</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203871</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>2.8</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>204</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203872</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>36.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>231</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203868</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>2.5</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>143</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203870</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>5.9</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>201</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FPHCLAFSYM</LinearSequence>
                        <StartingPosition>530</StartingPosition>
                        <EndingPosition>539</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAA10434.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>17304</EpitopeId>
                <ReferenceStartingPosition>530</ReferenceStartingPosition>
                <ReferenceEndingPosition>539</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356905</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>45</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 530</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FPHCLAFSYM</LinearSequence>
                                        <StartingPosition>530</StartingPosition>
                                        <EndingPosition>539</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>2</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356903</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>195</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 530</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FPHCLAFSYM</LinearSequence>
                                        <StartingPosition>530</StartingPosition>
                                        <EndingPosition>539</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356904</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>40</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 530</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FPHCLAFSYM</LinearSequence>
                                        <StartingPosition>530</StartingPosition>
                                        <EndingPosition>539</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>4</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356902</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>251</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 530</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FPHCLAFSYM</LinearSequence>
                                        <StartingPosition>530</StartingPosition>
                                        <EndingPosition>539</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203874</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>33.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>195</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203876</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>118.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>44</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203873</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>56.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>251</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203877</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>208.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>45</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203875</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>61.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>40</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GLLGWSPQA</LinearSequence>
                        <StartingPosition>62</StartingPosition>
                        <EndingPosition>70</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAC87019.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>20999</EpitopeId>
                <ReferenceStartingPosition>62</ReferenceStartingPosition>
                <ReferenceEndingPosition>70</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203879</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>14333.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>200</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203881</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>1321.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>204</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203880</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>286.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>201</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203878</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>13.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>143</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203882</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>231</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GLSRYVARL</LinearSequence>
                        <StartingPosition>442</StartingPosition>
                        <EndingPosition>450</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAA10434.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>21145</EpitopeId>
                <ReferenceStartingPosition>442</ReferenceStartingPosition>
                <ReferenceEndingPosition>450</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356853</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>203</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GLSRYVARL</LinearSequence>
                                        <StartingPosition>442</StartingPosition>
                                        <EndingPosition>450</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>1</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.  The majority of responsiveness was observed in individuals with the A*0201 background.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1353497</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>143</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GLSRYVARL</LinearSequence>
                                        <StartingPosition>442</StartingPosition>
                                        <EndingPosition>450</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>11</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>8</NumberOfSubjectsResponded>
                            <ResponseFrequency>72.7</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.  The majority of responsiveness was observed in individuals with the A*0201 background, but was also observed in one A*0202 individual.  This epitope was found to be degenerate, recognized in the context of multiple supertype alleles.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356852</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>200</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GLSRYVARL</LinearSequence>
                                        <StartingPosition>442</StartingPosition>
                                        <EndingPosition>450</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>1</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.  The majority of responsiveness was observed in individuals with the A*0201 background.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203885</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>18.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>201</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203886</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>12333.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>204</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203883</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>79.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>143</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203887</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>231</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203884</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>391.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>200</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GTDNSVVLSR</LinearSequence>
                        <StartingPosition>735</StartingPosition>
                        <EndingPosition>744</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAA10434.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>22628</EpitopeId>
                <ReferenceStartingPosition>735</ReferenceStartingPosition>
                <ReferenceEndingPosition>744</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203888</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>10000.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>211</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203890</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>20000.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>225</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203891</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>226</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203892</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>20000.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>230</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203889</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>107.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>213</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GTDNSVVLSRK</LinearSequence>
                        <StartingPosition>735</StartingPosition>
                        <EndingPosition>745</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAA10434.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>22629</EpitopeId>
                <ReferenceStartingPosition>735</ReferenceStartingPosition>
                <ReferenceEndingPosition>745</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203894</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>11.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>213</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203895</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>225</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203897</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>230</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203893</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>786.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>211</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203896</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>226</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>HPAAMPHLL</LinearSequence>
                        <StartingPosition>429</StartingPosition>
                        <EndingPosition>437</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAA10434.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>24420</EpitopeId>
                <ReferenceStartingPosition>429</ReferenceStartingPosition>
                <ReferenceEndingPosition>437</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356893</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>45</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 429</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>HPAAMPHLL</LinearSequence>
                                        <StartingPosition>429</StartingPosition>
                                        <EndingPosition>437</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>2</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356891</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>195</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 429</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>HPAAMPHLL</LinearSequence>
                                        <StartingPosition>429</StartingPosition>
                                        <EndingPosition>437</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356890</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>251</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 429</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>HPAAMPHLL</LinearSequence>
                                        <StartingPosition>429</StartingPosition>
                                        <EndingPosition>437</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356892</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>40</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 429</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>HPAAMPHLL</LinearSequence>
                                        <StartingPosition>429</StartingPosition>
                                        <EndingPosition>437</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>4</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203899</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>267.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>195</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203901</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>186.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>44</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203898</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>56.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>251</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203902</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>833.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>45</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203900</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>500.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>40</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>HPAAMPHLLV</LinearSequence>
                        <StartingPosition>429</StartingPosition>
                        <EndingPosition>438</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAA10434.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>24421</EpitopeId>
                <ReferenceStartingPosition>429</ReferenceStartingPosition>
                <ReferenceEndingPosition>438</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203905</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>705.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>40</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203907</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>588.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>45</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203906</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>664.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>44</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203904</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>3600.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>195</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203903</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>344.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>251</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>HTLWKAGILY</LinearSequence>
                        <StartingPosition>149</StartingPosition>
                        <EndingPosition>158</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAA10434.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>24942</EpitopeId>
                <ReferenceStartingPosition>149</ReferenceStartingPosition>
                <ReferenceEndingPosition>158</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203910</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>225</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203909</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>7500.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>213</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203911</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>8529.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>226</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203908</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>250.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>211</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203912</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>6667.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>230</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>HTLWKAGILYK</LinearSequence>
                        <StartingPosition>149</StartingPosition>
                        <EndingPosition>159</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAA10434.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>24943</EpitopeId>
                <ReferenceStartingPosition>149</ReferenceStartingPosition>
                <ReferenceEndingPosition>159</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356861</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>245</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 149-159</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>HTLWKAGILYK</LinearSequence>
                                        <StartingPosition>149</StartingPosition>
                                        <EndingPosition>159</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>2</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356859</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>242</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 149-159</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>HTLWKAGILYK</LinearSequence>
                                        <StartingPosition>149</StartingPosition>
                                        <EndingPosition>159</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>11</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>9.1</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356860</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>234</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 149-159</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>HTLWKAGILYK</LinearSequence>
                                        <StartingPosition>149</StartingPosition>
                                        <EndingPosition>159</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>6</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV  failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356862</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>230</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 149-159</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>HTLWKAGILYK</LinearSequence>
                                        <StartingPosition>149</StartingPosition>
                                        <EndingPosition>159</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to  recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203914</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>14.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>213</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203916</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>403.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>226</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203915</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>486.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>225</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203917</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>42.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>230</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203913</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>20.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>211</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>IPIPSSWAF</LinearSequence>
                        <StartingPosition>313</StartingPosition>
                        <EndingPosition>321</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAC87019.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>27878</EpitopeId>
                <ReferenceStartingPosition>313</ReferenceStartingPosition>
                <ReferenceEndingPosition>321</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356894</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>251</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Env 313</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IPIPSSWAF</LinearSequence>
                                        <StartingPosition>313</StartingPosition>
                                        <EndingPosition>321</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAC87019.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356895</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>195</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Env 313</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IPIPSSWAF</LinearSequence>
                                        <StartingPosition>313</StartingPosition>
                                        <EndingPosition>321</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAC87019.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356897</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>45</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Env 313</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IPIPSSWAF</LinearSequence>
                                        <StartingPosition>313</StartingPosition>
                                        <EndingPosition>321</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAC87019.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>2</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356896</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>40</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Env 313</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IPIPSSWAF</LinearSequence>
                                        <StartingPosition>313</StartingPosition>
                                        <EndingPosition>321</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAC87019.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>4</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>25</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203919</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>2.6</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>195</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203922</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>833.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>45</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203918</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>29.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>251</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203921</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>7.2</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>44</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203920</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>220.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>40</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KVGNFTGLY</LinearSequence>
                        <StartingPosition>55</StartingPosition>
                        <EndingPosition>63</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAA10434.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>34027</EpitopeId>
                <ReferenceStartingPosition>55</ReferenceStartingPosition>
                <ReferenceEndingPosition>63</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356864</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>234</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 55</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KVGNFTGLY</LinearSequence>
                                        <StartingPosition>55</StartingPosition>
                                        <EndingPosition>63</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>6</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>16.7</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.  The responsiveness was observed only in an HLA-A11 type individual.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356865</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>245</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 55</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KVGNFTGLY</LinearSequence>
                                        <StartingPosition>55</StartingPosition>
                                        <EndingPosition>63</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>2</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356863</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>242</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 55</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KVGNFTGLY</LinearSequence>
                                        <StartingPosition>55</StartingPosition>
                                        <EndingPosition>63</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>11</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>9.1</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356866</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>230</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 55</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KVGNFTGLY</LinearSequence>
                                        <StartingPosition>55</StartingPosition>
                                        <EndingPosition>63</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to  recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203923</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>37.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>211</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203924</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>429.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>213</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203926</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>226</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203925</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>225</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203927</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>230</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LPSDFFPSV</LinearSequence>
                        <StartingPosition>19</StartingPosition>
                        <EndingPosition>27</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAB41699.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>38701</EpitopeId>
                <ReferenceStartingPosition>19</ReferenceStartingPosition>
                <ReferenceEndingPosition>27</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356898</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>251</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Core 19</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LPSDFFPSV</LinearSequence>
                                        <StartingPosition>19</StartingPosition>
                                        <EndingPosition>27</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAB41699.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>4</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356899</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>195</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Core 19</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LPSDFFPSV</LinearSequence>
                                        <StartingPosition>19</StartingPosition>
                                        <EndingPosition>27</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAB41699.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>6</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356900</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>40</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Core 19</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LPSDFFPSV</LinearSequence>
                                        <StartingPosition>19</StartingPosition>
                                        <EndingPosition>27</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAB41699.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>4</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>50</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356901</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>45</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Core 19</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LPSDFFPSV</LinearSequence>
                                        <StartingPosition>19</StartingPosition>
                                        <EndingPosition>27</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAB41699.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>2</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203932</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>4.8</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>45</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203928</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>1774.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>251</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203930</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>9.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>40</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203929</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>171.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>195</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203931</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>120.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>44</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LVVDFSQFSR</LinearSequence>
                        <StartingPosition>377</StartingPosition>
                        <EndingPosition>386</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAA10434.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>40624</EpitopeId>
                <ReferenceStartingPosition>377</ReferenceStartingPosition>
                <ReferenceEndingPosition>386</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356869</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>245</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 377</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LVVDFSQFSR</LinearSequence>
                                        <StartingPosition>377</StartingPosition>
                                        <EndingPosition>386</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>2</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356868</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>234</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 377</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LVVDFSQFSR</LinearSequence>
                                        <StartingPosition>377</StartingPosition>
                                        <EndingPosition>386</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>7</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>14.3</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.  The responsiveness was observed only in an HLA-A11 type individual.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356867</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>242</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 377</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LVVDFSQFSR</LinearSequence>
                                        <StartingPosition>377</StartingPosition>
                                        <EndingPosition>386</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>11</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356870</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>230</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 377</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LVVDFSQFSR</LinearSequence>
                                        <StartingPosition>377</StartingPosition>
                                        <EndingPosition>386</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>2</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to  recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203936</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>126.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>226</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203937</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>16.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>230</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203933</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>6875.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>211</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203935</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>602.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>225</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203934</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>17.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>213</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>MMWYWGPSLY</LinearSequence>
                        <StartingPosition>360</StartingPosition>
                        <EndingPosition>369</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAC87019.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>42184</EpitopeId>
                <ReferenceStartingPosition>360</ReferenceStartingPosition>
                <ReferenceEndingPosition>369</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203940</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>225</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203938</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>220.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>211</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203942</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>230</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203941</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>226</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203939</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>7500.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>213</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NVSIPWTHK</LinearSequence>
                        <StartingPosition>47</StartingPosition>
                        <EndingPosition>55</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAA10434.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>46480</EpitopeId>
                <ReferenceStartingPosition>47</ReferenceStartingPosition>
                <ReferenceEndingPosition>55</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1353500</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>242</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 47</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NVSIPWTHK</LinearSequence>
                                        <StartingPosition>47</StartingPosition>
                                        <EndingPosition>55</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>11</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356856</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>234</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 47</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NVSIPWTHK</LinearSequence>
                                        <StartingPosition>47</StartingPosition>
                                        <EndingPosition>55</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>6</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>16.7</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.  The responsiveness was observed only in an HLA-A11 type individual.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356857</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>245</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 47</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NVSIPWTHK</LinearSequence>
                                        <StartingPosition>47</StartingPosition>
                                        <EndingPosition>55</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>2</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356858</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>230</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 47</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NVSIPWTHK</LinearSequence>
                                        <StartingPosition>47</StartingPosition>
                                        <EndingPosition>55</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>2</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to  recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203946</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>2900.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>226</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203947</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>250.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>230</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203943</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>134.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>211</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203944</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>105.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>213</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203945</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>225</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>PVNRPIDWK</LinearSequence>
                        <StartingPosition>612</StartingPosition>
                        <EndingPosition>620</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAA10434.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>49923</EpitopeId>
                <ReferenceStartingPosition>612</ReferenceStartingPosition>
                <ReferenceEndingPosition>620</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203952</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>8889.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>230</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203950</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>225</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203948</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>355.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>211</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203949</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>43.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>213</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203951</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>226</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>QAFTFSPTYK</LinearSequence>
                        <StartingPosition>654</StartingPosition>
                        <EndingPosition>663</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAA10434.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>50253</EpitopeId>
                <ReferenceStartingPosition>654</ReferenceStartingPosition>
                <ReferenceEndingPosition>663</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356872</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>234</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 654</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QAFTFSPTYK</LinearSequence>
                                        <StartingPosition>654</StartingPosition>
                                        <EndingPosition>663</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>6</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>16.7</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.  The responsiveness was observed only in an HLA-A11 type individual.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356873</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>245</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 654</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QAFTFSPTYK</LinearSequence>
                                        <StartingPosition>654</StartingPosition>
                                        <EndingPosition>663</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>2</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356871</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>242</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 654</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QAFTFSPTYK</LinearSequence>
                                        <StartingPosition>654</StartingPosition>
                                        <EndingPosition>663</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>11</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>18.2</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356874</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>230</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 654</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QAFTFSPTYK</LinearSequence>
                                        <StartingPosition>654</StartingPosition>
                                        <EndingPosition>663</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>2</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to  recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203954</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>11.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>213</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203956</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>5088.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>226</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203953</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>244.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>211</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203955</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>18000.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>225</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203957</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>6.7</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>230</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>RVTGGVFLVDK</LinearSequence>
                        <StartingPosition>357</StartingPosition>
                        <EndingPosition>367</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAA10434.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>56428</EpitopeId>
                <ReferenceStartingPosition>357</ReferenceStartingPosition>
                <ReferenceEndingPosition>367</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203960</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>225</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203961</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>226</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203958</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>579.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>211</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203962</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>230</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203959</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>207.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>213</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SAICSVVRR</LinearSequence>
                        <StartingPosition>520</StartingPosition>
                        <EndingPosition>528</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAA10434.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>56814</EpitopeId>
                <ReferenceStartingPosition>520</ReferenceStartingPosition>
                <ReferenceEndingPosition>528</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356877</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>245</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 520</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SAICSVVRR</LinearSequence>
                                        <StartingPosition>520</StartingPosition>
                                        <EndingPosition>528</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>2</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>50</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356876</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>234</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 520</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SAICSVVRR</LinearSequence>
                                        <StartingPosition>520</StartingPosition>
                                        <EndingPosition>528</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>6</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognized targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356875</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>242</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 520</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SAICSVVRR</LinearSequence>
                                        <StartingPosition>520</StartingPosition>
                                        <EndingPosition>528</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>11</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>9.1</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356878</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>230</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 520</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SAICSVVRR</LinearSequence>
                                        <StartingPosition>520</StartingPosition>
                                        <EndingPosition>528</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to  recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203964</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>29.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>213</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203965</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>1200.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>225</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203967</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>21.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>230</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203963</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>1897.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>211</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203966</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>446.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>226</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>STLPETTVVR</LinearSequence>
                        <StartingPosition>170</StartingPosition>
                        <EndingPosition>179</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAO62974.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>61743</EpitopeId>
                <ReferenceStartingPosition>170</ReferenceStartingPosition>
                <ReferenceEndingPosition>179</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203971</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>1208.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>226</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203970</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>2250.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>225</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203968</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>15714.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>211</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203969</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>100.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>213</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203972</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>320.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>230</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>STLPETTVVRR</LinearSequence>
                        <StartingPosition>141</StartingPosition>
                        <EndingPosition>151</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAB41699.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>61745</EpitopeId>
                <ReferenceStartingPosition>141</ReferenceStartingPosition>
                <ReferenceEndingPosition>151</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356879</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>242</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Core 141</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>STLPETTVVRR</LinearSequence>
                                        <StartingPosition>141</StartingPosition>
                                        <EndingPosition>151</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAB41699.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>13</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356881</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>245</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Core 141</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>STLPETTVVRR</LinearSequence>
                                        <StartingPosition>141</StartingPosition>
                                        <EndingPosition>151</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAB41699.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>6</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>50</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356882</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>230</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Core 141</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>STLPETTVVRR</LinearSequence>
                                        <StartingPosition>141</StartingPosition>
                                        <EndingPosition>151</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAB41699.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>7</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>4</NumberOfSubjectsResponded>
                            <ResponseFrequency>57.1</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV  recognized targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356880</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>234</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Core 141</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>STLPETTVVRR</LinearSequence>
                                        <StartingPosition>141</StartingPosition>
                                        <EndingPosition>151</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAB41699.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>6</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>16.7</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.  The responsiveness was observed only in an HLA-A11 type individual.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203977</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>26.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>230</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203973</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>733.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>211</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203976</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>181.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>226</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203974</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>4.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>213</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203975</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>181.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>225</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TLPETTVVRR</LinearSequence>
                        <StartingPosition>171</StartingPosition>
                        <EndingPosition>180</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAO62974.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>65001</EpitopeId>
                <ReferenceStartingPosition>171</ReferenceStartingPosition>
                <ReferenceEndingPosition>180</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203982</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>182.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>230</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203981</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>2417.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>226</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203980</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>225</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203978</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>15714.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>211</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203979</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>261.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>213</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TLWKAGILY</LinearSequence>
                        <StartingPosition>150</StartingPosition>
                        <EndingPosition>158</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAA10434.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>65147</EpitopeId>
                <ReferenceStartingPosition>150</ReferenceStartingPosition>
                <ReferenceEndingPosition>158</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203984</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>7500.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>213</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203986</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>226</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203983</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>85.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>211</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203985</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>225</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203987</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>230</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TLWKAGILYK</LinearSequence>
                        <StartingPosition>150</StartingPosition>
                        <EndingPosition>159</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAA10434.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>65148</EpitopeId>
                <ReferenceStartingPosition>150</ReferenceStartingPosition>
                <ReferenceEndingPosition>159</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356885</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>245</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 150</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TLWKAGILYK</LinearSequence>
                                        <StartingPosition>150</StartingPosition>
                                        <EndingPosition>159</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>2</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356884</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>234</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 150</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TLWKAGILYK</LinearSequence>
                                        <StartingPosition>150</StartingPosition>
                                        <EndingPosition>159</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>9</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>11.1</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.  The responsiveness was observed only in an HLA-A11 type individual.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356883</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>242</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 150</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TLWKAGILYK</LinearSequence>
                                        <StartingPosition>150</StartingPosition>
                                        <EndingPosition>159</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>15</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>4</NumberOfSubjectsResponded>
                            <ResponseFrequency>26.7</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356886</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>230</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 150</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TLWKAGILYK</LinearSequence>
                                        <StartingPosition>150</StartingPosition>
                                        <EndingPosition>159</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>2</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to  recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203991</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>226</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203988</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>2.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>211</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203990</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>3529.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>225</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203992</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>615.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>230</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203989</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>17.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>213</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TPARVTGGVF</LinearSequence>
                        <StartingPosition>354</StartingPosition>
                        <EndingPosition>363</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAA10434.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>65509</EpitopeId>
                <ReferenceStartingPosition>354</ReferenceStartingPosition>
                <ReferenceEndingPosition>363</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356907</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>195</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 354</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TPARVTGGVF</LinearSequence>
                                        <StartingPosition>354</StartingPosition>
                                        <EndingPosition>363</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356906</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>251</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 354</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TPARVTGGVF</LinearSequence>
                                        <StartingPosition>354</StartingPosition>
                                        <EndingPosition>363</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356909</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>45</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 354</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TPARVTGGVF</LinearSequence>
                                        <StartingPosition>354</StartingPosition>
                                        <EndingPosition>363</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>2</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356908</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>40</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 354</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TPARVTGGVF</LinearSequence>
                                        <StartingPosition>354</StartingPosition>
                                        <EndingPosition>363</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>4</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>50</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203994</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>72.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>195</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203996</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>939.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>44</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203995</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>40</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203993</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>17.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>251</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203997</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>16667.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>45</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>VTGGVFLVDK</LinearSequence>
                        <StartingPosition>358</StartingPosition>
                        <EndingPosition>367</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAA10434.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>71322</EpitopeId>
                <ReferenceStartingPosition>358</ReferenceStartingPosition>
                <ReferenceEndingPosition>367</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204000</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>225</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204001</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>226</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203999</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>65.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>213</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204002</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>3636.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>230</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>203998</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>282.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>211</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>VVDFSQFSR</LinearSequence>
                        <StartingPosition>378</StartingPosition>
                        <EndingPosition>386</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAA10434.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>71631</EpitopeId>
                <ReferenceStartingPosition>378</ReferenceStartingPosition>
                <ReferenceEndingPosition>386</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204003</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>7333.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>211</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204005</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>13846.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>225</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204007</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>320.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>230</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204004</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>80.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>213</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204006</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>1706.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>226</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>WLSLLVPFV</LinearSequence>
                        <StartingPosition>335</StartingPosition>
                        <EndingPosition>343</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAC87019.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>72794</EpitopeId>
                <ReferenceStartingPosition>335</ReferenceStartingPosition>
                <ReferenceEndingPosition>343</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356855</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>203</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Env 335</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>WLSLLVPFV</LinearSequence>
                                        <StartingPosition>335</StartingPosition>
                                        <EndingPosition>343</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAC87019.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>5</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>60</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.  The majority of responsiveness was observed in individuals with the A*0201 background.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1353496</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>143</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Env 335</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>WLSLLVPFV</LinearSequence>
                                        <StartingPosition>335</StartingPosition>
                                        <EndingPosition>343</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAC87019.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>23</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>19</NumberOfSubjectsResponded>
                            <ResponseFrequency>82.6</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.  The majority of responsiveness was observed in individuals with the A*0201 background, but was also observed in one A*0202 and three A*0205/6 individuals.  This epitope was found to be degenerate, recognized in the context of multiple supertype alleles.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356854</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>200</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Env 335</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>WLSLLVPFV</LinearSequence>
                                        <StartingPosition>335</StartingPosition>
                                        <EndingPosition>343</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAC87019.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>1</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>CTLs from patients acutely infected with HBV recognized targets expressing the epitope.  The majority of responsiveness was observed in individuals with the A*0201 background.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204009</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>113.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>200</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204010</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>1.4</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>201</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204011</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>10.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>204</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204012</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>1290.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>231</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204008</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>4.5</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>143</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>YMDDVVLGA</LinearSequence>
                        <StartingPosition>538</StartingPosition>
                        <EndingPosition>546</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAA10434.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>75040</EpitopeId>
                <ReferenceStartingPosition>538</ReferenceStartingPosition>
                <ReferenceEndingPosition>546</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204014</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>200</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204017</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>231</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204013</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>200.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>143</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204016</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>204</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204015</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>4167.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>201</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>YMDDVVLGAK</LinearSequence>
                        <StartingPosition>538</StartingPosition>
                        <EndingPosition>547</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAA10434.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>75041</EpitopeId>
                <ReferenceStartingPosition>538</ReferenceStartingPosition>
                <ReferenceEndingPosition>547</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204018</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>333.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>211</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204022</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>230</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204021</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>226</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204020</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <QuantitativeMeasurement>25000.0</QuantitativeMeasurement>
                            <MeasurementInequality>&gt;</MeasurementInequality>
                        </AssayInformation>
                        <MhcAlleleId>225</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204019</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>417</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>1395.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>213</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>YPALMPLYA</LinearSequence>
                        <StartingPosition>640</StartingPosition>
                        <EndingPosition>648</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAA10434.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>75257</EpitopeId>
                <ReferenceStartingPosition>640</ReferenceStartingPosition>
                <ReferenceEndingPosition>648</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Imported from the TopBank database.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1353512</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>251</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 640</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YPALMPLYA</LinearSequence>
                                        <StartingPosition>640</StartingPosition>
                                        <EndingPosition>648</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356888</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>40</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 640</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YPALMPLYA</LinearSequence>
                                        <StartingPosition>640</StartingPosition>
                                        <EndingPosition>648</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>4</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356889</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>45</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 640</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YPALMPLYA</LinearSequence>
                                        <StartingPosition>640</StartingPosition>
                                        <EndingPosition>648</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>2</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table IV</LocationOfData>
                        <TCellId>1356887</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The study included 95 HLA-typed patients with acute HBV infection.  The diagnosis of acute hepatitis B was based on clinical and biochemical evidence of acute liver injury, according to standard diagnostic criteria, including serum alanine amino transferase activity at least 10-fold greater than the upper normal limit, together with serological evidence of acute HBV infection, including hepatitis B surface antigen (HBsAg) and IgM anti-HBc antibody (IgM HBc-Ab) and the absence of serologic evidence of hepatitis D and hepatitis C virus (Abbott Laboratories, North Chicago, IL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>195</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBV Pol 640</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YPALMPLYA</LinearSequence>
                                        <StartingPosition>640</StartingPosition>
                                        <EndingPosition>648</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAA10434.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>CTLs from patients acutely infected with HBV failed to recognize targets expressing the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204023</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>306.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>251</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204027</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <QuantitativeMeasurement>0.63</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>45</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204024</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>150.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>195</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204025</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <QuantitativeMeasurement>162.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>40</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Table III</LocationOfData>
                        <MhcBindingId>204026</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>1</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <QuantitativeMeasurement>664.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <MhcAlleleId>44</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

